cyrilzakka/clinical-trials huggingface dataset:
Upper Extremity Function, Shoulder Position Sense and Disability Level İn Patients With Multiple Sclerosis

The purposes of this study is to investigate the relationship between upper extremity muscle function and shoulder position sense in patients with Multiple Sclerosis (MS) and which best projects the disability status.

Upper extremity dysfunction is considered to be the main cause of the loss performance of activities of daily living and this problem was include all motor and somatosensory components of function. Any failure in each of these components will likely create an impairment in the normal function.

One of the most important components of the somatosensory system is joint position sense, a sub-modality of proprioception. Position sense disorders are seen from the early stages of the disease and upper extremity function problems is experienced depending on position sense disorders in patients with MS.

Expanded Disability Status Scale (EDSS) is one of the most commonly outcome measures in evaluating the level of disability in MS population. Because EDSS scale emphasis on ambulation, so it is insensitive to upper extremity function. But the ability to use walking aids (e.g., canes, walkers, wheelchairs, etc.) may be affected by the UE impairment so shoulder position sense.

When literature is examined, there is no study which examines the relationship between upper extremity muscle function and shoulder position sense in patients with Multiple Sclerosis and which best projects the disability status. For all these reasons, we think that shoulder position sense is changed both dominant and non-dominant side during flexion and abduction movements in mild-moderate MS patients and that these deficits are correlated with upper extremity function and disability level.

This study was aimed to investigate the relationship between upper extremity muscle function and shoulder position sense in patients with MS and which best projects the disability status.

21 PwMS and 20 healthy volunteers with matching ages and genders were included the study. A neurologic examination was performed using the EDSS by a neurologist.

Upper extremity function was evaluated with 9-Hole Peg Test (9-HPT). Shoulder position sense was evaluated with Dualer IQTM digital inclinometer (J-TECH medical, Salt Lake City, UK, USA).

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of Multiple Sclerosis Disease
* The level of disability should be between 0.5-4 according to EDSS

Exclusion Criteria:

* Patients with acute attacks (three months prior to the study)
* Mini-Mental State Examination (MMSE) score of less tahn 25 points
* History of shoulder injury, surgery, medical problems or other neurological disorders in any of the participants
Precision Application of Clostridium Butyricm of Clinical Research on Osteoarthritis

Osteoarthritis (OA) is a common joint disease worldwide. The main symptom is that the mechanical wear of the cartilage in the joint and leads to the abnormal proliferation of the surrounding bone and synovial tissue with the chronic inflammation and the narrowing of the joint cavity. The prevalence of OA is increasing due to population increasing and aging, and there are currently about 400 million OA patients in worldwide. The treatment methods of osteoarthritis are mainly divided into medicine and non-medicine therapy. The major function of medicine therapy is to reduce pain and the arthroscopic surgery (arthroscopy) is main treatment of non-medicine therapy. Thus, in this project the investigators will mainly focus on the precise application of Clostridium butyricum on OA and the investigators' previous study successfully demonstrated the therapeutic effects of Clostridium butyricum on OA animal model. Therefore, will test the clinical effects of OA patient with Clostridium butyricum treatment, and whether it is also possible to improve the symptom of OA patients.


Eligibility Criteria:
Inclusion Criteria:

- A. Patients aged 55 to 75 years old with degenerative arthritis, diagnosed by a physician as suitable for participation in this experiment.

B. Patients with early-stage degenerative arthritis symptoms, as interpreted by X-ray using the Kellgren Lawrence Grading Scale at grade 1 or 2, and determined by a physician to not require long-term treatment.

C. Patients with a high pain index when the knee is extended 40-70 mm.

D. Patients who feel knee pain, primarily those with a high Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index score (pain scale score \>2.0 or total WOMAC scale score \>12).

Exclusion Criteria:

- A. Patients with a history of knee joint trauma or knee joint surgery (including arthroscopic surgery).

B. Patients who have taken steroid medication for the treatment of degenerative arthritis.

C. Patients with severe cardiovascular, cerebrovascular, rheumatic, or psychiatric diseases.

D. Patients with joint pain caused by other factors.

E. Patients with infectious diseases or acute infections (e.g., fever, localized inflammation, abscess).

F. Patients with systemic or metabolic diseases, or progressive bone degeneration caused by medication.

G. Cancer patients.
Determination of Drug Interactions of Certain Nasal Medications With Intranasal Ketamine

This is an open label, single-center study to determine whether certain nasal medication interact with PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers and in patients with allergic rhinitis.

To assess separately the effects of a nasal vasoconstrictor (oxymetazoline) and of a nasal steroid on the rate and extent of intranasal absorption of PMI-150 30 mg.

Eligibility Criteria:
Inclusion Criteria:

* Healthy adults
* Patients with Allergic Rhinitis

Exclusion Criteria:

* Under age 18
Registry to Investigate the Efficacy and Safety of VenaBlock VeIn SEaling System for VaRicose Veins in SingApore

To assess the efficacy of the Venablock©Vein Sealing System (VBVS) for the treatment of lower extremity superficial truncal veins in a real-world clinical setting in a multi-racial Asian population in Singapore.

The purpose of the Registry to Investigate the Efficacy and Safety of Venablock©Vein Sealing System for Varicose Veins in Singapore (RIVERIA), is to investigate the performance of cyanoacrylate glue closure (CAC) using this device, in which multiple incompetent superficial saphenous truncal veins (great saphenous (GSV), short saphenous vein (SSV), anterior accessory saphenous vein (AASV) will be treated at the same setting, and compression stockings will not be used post-operatively. The inclusion criteria for this study will be liberalized, and veins up to 12mm in diameter will be treated. As such,RIVIERA will be the first prospective trial conducted in Asia on a predominantly Asian cohort of patients to report on the performance of Venablock© for blocking incompetent truncal veins. This study specifically focuses on the initial technical outcomes, safety, anatomical occlusion, and patient experience after treatment with Venablock© with broader inclusion of patients than previous caucasian based trials.

Eligibility Criteria:
Inclusion Criteria:

1. Age \> 21 years old and ability to understand the requirements of the study and to provide informed consent
2. C2-C6 varicose veins/CVI (CEAP Class 1 patients will be excluded)
3. Symptomatic primary GSV,SSV or AASV incompetence, with reflux \> 0.5 seconds on colour Duplex, including one or more of the following symptoms: aching, throbbing, heaviness, fatigue, pruritus, night cramps, restlessness, generalized pain or discomfort, swelling
4. Patients who had GSV, SSV or AASV diameters of 3mm to 12mm in the standing position

Exclusion Criteria:

1. Current DVT or history of DVT
2. Pregnant patients
3. Arterial disease (ABPI\<0.8)
4. Sepsis
5. Patient who are unwilling to participate
6. Inability or unwillingness to complete the time-point questionnaires
7. Adverse reaction to sclerosant or cyanoacrylate previously
8. Multiple drug allergies
9. Previous intervention with the VenaSeal cyanoacrylate glue closure system
10. Severely tortuous GSV, SSV or AASV
11. Life expectancy \< 1 year
12. Active treatment for malignancy other than non-melanoma skin cancer
13. Current, regular use of systemic anticoagulation (e.g., warfarin, heparin)
14. Daily use of narcotic analgesia or NSAIDS to control pain associated with venous disease
Pediatric Healthy Weight Clinic

The overall goal of this study is to increase access to and adoption of the Healthy Weight Clinic package in primary care settings serving low income families in the United States who have a disproportionately high prevalence of childhood obesity. Two federally-qualified health centers in Mississippi and two health centers in Massachusetts will be implementing a Healthy Weight Clinic Program. The Healthy Weight Clinic is staffed by a medical provider, a Dietitian/Nutritionist, and a Community Healthy Worker. Patients attend individual medical visits (once per month for 12 months) with the multidisciplinary team, group visits led by a member of the team (once per month for 6 months), and phone follow-up between visits. All patients who receive care at the pilot implementation sites will be exposed to the systems-level intervention. A subset of patients will be invited to participate in a research evaluation of the program.


Eligibility Criteria:
Inclusion Criteria:

* child is age 2 through 18 years at referral
* child's BMI meets or exceeds the 85th percentile for age and sex
* parent can read and respond to interviews and questionnaires in English or Spanish
* received care at one of the participating pilot sites

Exclusion Criteria:

* children who do not have at least one parent who can report on their child's daily activities for 1 year
* families who plan to leave their pediatric health center in the next year
* children who have conditions or take medications that substantially interfere with growth, physical activity, or dietary recommendations
Cardiovascular Manifestations of COVID-19

Electronic medical record review of de-identified patients who tested positive for COVID-19 (using a PCR test) at Methodist Dallas Medical Center (MDMC) from June 2020 until the date of IRB approval. Data will be collected on de-identified patients that test positive for COVID-19 (using a PCR test) at MDMC from the date of IRB approval until December 2022. Disclaimer: Any cost associated with the procedures stated herein will be billed directly to you or to your insurance (as applicable)

Electronic medical record review of de-identified patients who tested positive for COVID-19 (using a PCR test) at Methodist Dallas Medical Center (MDMC) from June 2020 until the date of IRB approval. Data will be collected on de-identified patients that test positive for COVID-19 (using a PCR test) at MDMC from the date of IRB approval until December 2022. Variables include patient baseline characteristics, patient presentation, imaging and labs. Disclaimer: Any cost associated with the procedures stated herein will be billed directly to you or to your insurance (as applicable)

Eligibility Criteria:
Inclusion Criteria:

* Hospitalized patient
* Adult over 18 years
* Positive COVID-19 PCR Test

Exclusion Criteria:

* None
Objective Examination and Rehabilitation Treatment of Patients With BPPV

Dizziness (BPPV) causes severe deterioration in quality of life, incoordination, and instability.

In the study, we selected a minimum of 100 patients with BPPV who were examined after specialist care. After the acute phase, a physical survey is performed where movement and coordination are examined.

After the results, the patients undergo a rehabilitation training. The workout is submaximal and high intensity that is done for 3 weeks.

Hypothesis: As a result of training, it is possible that the remaining feeling of dizziness and insecurity, impaired coordination will decrease or disappear.


Eligibility Criteria:
Inclusion Criteria:

* For a patient with BPPV
* With a lack of coordination
* Dizziness
* Ear nose laryngeal examination
* Neurological examination

Exclusion Criteria:

* other neurological diseases
* cardiological diseases
* underwent surgery
* severe joint pain
* alcoholism
* dementia
* drug
Role of Immunoglobulin in Male Infertility

to investigate the role of IVIG in male infertility and to determine its benefits in term of semen parameters and assisted reproduction outcome


Eligibility Criteria:
Inclusion Criteria:

* male patients

Exclusion Criteria:

* female
The Impact of Thread Length on Implant Stability

Some studies show that different types of threads in tapered implants result in differences in primary stability. The aim of this study is to a perform a prospective, controlled, randomized clinical trial comparing primary and secondary stability between long and standard thread implants in the treatment of partial edentulous patients.

The study sample consists of 23 maxillary partial edentulous patients, where 32 implants were placed, with threads of 0.7 mm or 0.3 mm in the location of premolars and molars. The comparison, in terms of primary stability, is made by measuring the ISQ value (implant stability quotient), in four locations (buccal, palatal, mesial and distal). Statistical analysis was performed using the independent T-Test.

Eligibility Criteria:
Inclusion Criteria:

* Minimum 18 years;
* No systemic conditions that contraindicate surgery;
* Periodontal health or periodontal disease treated as part of a periodontal support program and having a high level of plaque control;
* Partial edentulous patients, in the upper jaw, specifically in the location of premolars and molars;

Exclusion Criteria:

* Patients with insufficient quantity of bone for implant placement without bone regeneration procedures;
* Patients who underwent medication that could affect stability and osteointegration up to 3 months prior to study initiation;
* Patients with untreated periodontal pathology or who have not followed periodontal supportive treatment;
* Smokers, Pregnant or lactating women.
The Effect of Workplace Interventions on the Treatment of Low-back Pain

The study evaluates the effect of workplace interventions on work ability promotion among workers with back problems. The half of participant will receive Information, advice and guidance for back problems in addition to participatory workplace actions organized by Occupational Health Physiotherapist. The other half will receive only Information, advice and guidance without workplace intervention.

Musculoskeletal symptoms, especially back pain, account for the majority of days lost.

In order to enhance the health and working careers of people with MSD, it is important that work can be arranged in such a way that they can remain in work life despite MSD.In the field of work ability promotion, various stakeholders; the worker, employer, professionals in occupational health services (OHS) interact to optimize actions and practices to prevent absences from work and promote remaining at work. This study aims to investigate participatory working practices and modles of co-operation among OHS and workplaces.

Eligibility Criteria:
Inclusion Criteria:

* Back pain for at least two weeks or frequently occuring periods within the past 12 months

Exclusion Criteria:

* Back problems with forcoming surcical operation
Mulligan Mobilization With Laser for Shoulder Adhesive Capsulitis

Adhesive capsulitis (frozen shoulder) is a condition of uncertain etiology characterized by pain and progressive loss of both active and passive shoulder motion.

Shoulder pain and stiffness are accompanied by disability. It is thought that the incidence is 3 to 5% in the general population. Laser therapy is widely used for treating different musculoskeletal diseases, because of its ability to reduce pain and improve the physical function. Also, MWM when used for shoulders with limited range of motion because of pain had shown improvement in range of motion and pressure pain threshold. Previous studies have investigated the efficacy of combining different manual technique with LLLT for treating pain in some body parts. However, up till now the combined effect of MWM with LLLT for treatment of patients with shoulder adhesive capsulitis have not been investigated.

So, the present randomized controlled study will be conducted to investigate the effect of adding mulligan mobilization with movement to low level laser therapy in treatment of patients with shoulder adhesive capsulitis.


Eligibility Criteria:
Inclusion Criteria:

* The participant selected for the study were patients (both male and female).
* Subjects diagnosed diagnosed by physicians with Magnetic Resonance Imaging (MRI).

  \& referred by an Orthopedician with stage 2 Adhesive Capsulitis.
* Age group of 40-60 years of old.
* painful condition of at least 3 months with 50% restriction in passive shoulder flexion, abduction and external rotation, in a sagittal plane compared with opposite side.
* The severity of pain on visual analogue scale was higher than three out of ten, pain aggravated by movements.
* patients were suffering from pain and limitation in the motion for more than 3 month.

Exclusion Criteria:

* Patients with any shoulder injury or trauma, surgical release of capsule.
* Previous manipulation done under anaesthesia of the affected shoulder in the preceding 4 weeks.
* Other conditions involving the shoulder (eg. rheumatoid arthritis, osteoarthritis, damage of the glenohumeral cartilage, osteoporosis, or malignancies in the shoulder region).
* Pain or disorders of the cervical spine, elbow, wrist, or hand.
* Presence of medical conditions such as cardiac disease, infections, coagulation disorder.
* patients having any intra articular injection, or physiotherapy treatment in the affected shoulder during the last three months.
* patients with musculoskeletal disorder (any type of fracture), any history of surgery on that shoulder and patients with tendon calcification, patients with cervical rib, rotator cuff tear patients.
* Patients have insulin-dependent diabetes mellitus.
* Bilateral Frozen Shoulder
* systemic inflammatory joint disease (such as rheumatoid arthritis or polymyalgia rheumatica).
Down Syndrome Metabolic Health Study

The purpose of this research study is to determine which measures best capture cardiovascular disease (CVD) risk and type 2 diabetes (T2DM) risk in children and adolescents with Down syndrome (DS).

We hypothesize that DS is associated with worse cardiometabolic risk factors for a given body mass index compared to controls. This difference arises at least in part, from increased fat tissue.

DS affects 1 per 800 births and is one of the most common causes of developmental disability in the US. Life expectancy for Down syndrome has increased significantly: estimated median survival in the US in 1997 was 49 years. DS is associated with an increased risk for obesity, with an estimated prevalence of 47-48% in adults and 30-50% in children with DS. Adolescents with DS are more likely to have increased adiposity compared to unaffected peers and may be at increased risk for obesity-related co-morbidities, such as type 2 diabetes and cardiovascular disease. How one defines obesity in DS is not clear. Individuals with DS have short stature and possibly increased adiposity, and the body mass index (BMI) used to define obesity for otherwise healthy populations may not accurately depict body fatness or capture cardiometabolic risk in DS.

Congenital heart disease (CHD) affects approximately 50% of individuals with DS; the National Institutes of Health Heart Lung and Blood Institute (NHLBI) Working Group on Obesity and Other Cardiovascular Risk Factors in Congenital Heart Disease highlighted the high prevalence of obesity in the setting of CHD, and called for studies to identify obesity measures that are more sensitive than BMI as well as studies of CVD risk prevention. Unfortunately, clinicians caring for obese adolescents with DS with or without CHD have little scientific evidence upon which to base guidance regarding cardiometabolic risk (CMR): data regarding CVD risk and prevalence of pre-diabetes and T2DM in obese adolescents with DS are lacking.

The measure of body fatness which best predicts CMR in DS is not known. We plan to compare BMI and other measures of body fatness in healthy controls and adolescents with DS to determine which measures best capture CVD and/or T2DM risk. These data will equip medical providers with the tools to better assess risk, initiate prevention measures, and guide screening in adolescents with DS.

Eligibility Criteria:
Inclusion Criteria:

* Both groups: Ages 10 - 20
* Both groups: Parental/guardian permission (informed consent) and if appropriate, child assent.
* Down syndrome group only: diagnosis of Down syndrome

Exclusion Criteria (both groups):

* Major organ system illness (such as leukemia), except for type 2 Diabetes
* Cyanotic congenital heart disease and/or pulmonary hypertension
* Medically unstable congenital heart disease
* Pregnancy
* Genetic syndrome known to affect glucose tolerance
* Familial hypercholesterolemia
* Currently treated with medications known to affect insulin sensitivity (other than diabetes agents in participants with type 2 diabetes)